120 related articles for article (PubMed ID: 32487648)
1. Cytoplasmic Expression of AXL Is Associated With High Risk of Postoperative Relapse of Conventional Renal Cell Carcinoma.
Peterfi L; Bjercke T; Yusenko MV; Kovacs G; Banyai D
Anticancer Res; 2020 Jun; 40(6):3485-3489. PubMed ID: 32487648
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival.
Gustafsson A; Martuszewska D; Johansson M; Ekman C; Hafizi S; Ljungberg B; Dahlbäck B
Clin Cancer Res; 2009 Jul; 15(14):4742-9. PubMed ID: 19567592
[TBL] [Abstract][Full Text] [Related]
3. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model.
Chen TJ; Mydel P; Benedyk-Machaczka M; Kamińska M; Kalucka U; Blø M; Furriol J; Gausdal G; Lorens J; Osman T; Marti HP
Physiol Rep; 2021 Dec; 9(23):e15140. PubMed ID: 34877810
[TBL] [Abstract][Full Text] [Related]
4. LncRNA HOTAIR regulates HIF-1α/AXL signaling through inhibition of miR-217 in renal cell carcinoma.
Hong Q; Li O; Zheng W; Xiao WZ; Zhang L; Wu D; Cai GY; He JC; Chen XM
Cell Death Dis; 2017 May; 8(5):e2772. PubMed ID: 28492542
[TBL] [Abstract][Full Text] [Related]
5. Lack of TMEM27 expression is associated with postoperative progression of clinically localized conventional renal cell carcinoma.
Javorhazy A; Farkas N; Beothe T; Pusztai C; Szanto A; Kovacs G
J Cancer Res Clin Oncol; 2016 Sep; 142(9):1947-53. PubMed ID: 27417314
[TBL] [Abstract][Full Text] [Related]
6. High Novel Oncogene with Kinase-Domain (NOK) Gene Expression is Associated with the Progression of Renal Cell Carcinoma.
Cao Q; Chen M; Li Z; Huang W; Jin Y; Ye X; Tong M
Clin Lab; 2016; 62(1-2):179-86. PubMed ID: 27012048
[TBL] [Abstract][Full Text] [Related]
7. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma.
Yu H; Liu R; Ma B; Li X; Yen HY; Zhou Y; Krasnoperov V; Xia Z; Zhang X; Bove AM; Buscarini M; Parekh D; Gill IS; Liao Q; Tretiakova M; Quinn D; Zhao J; Gill PS
Br J Cancer; 2015 Aug; 113(4):616-25. PubMed ID: 26180925
[TBL] [Abstract][Full Text] [Related]
8. Axl is a prognostic marker in oral squamous cell carcinoma.
Lee CH; Yen CY; Liu SY; Chen CK; Chiang CF; Shiah SG; Chen PH; Shieh YS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S500-8. PubMed ID: 21842265
[TBL] [Abstract][Full Text] [Related]
9. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
[TBL] [Abstract][Full Text] [Related]
10. S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma.
Xiao Y; Zhao H; Tian L; Nolley R; Diep AN; Ernst A; Fuh KC; Miao YR; von Eyben R; Leppert JT; Brooks JD; Peehl DM; Giaccia AJ; Rankin EB
Cancer Res; 2019 Nov; 79(22):5758-5768. PubMed ID: 31585940
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic expression of β-catenin is an independent predictor of progression of conventional renal cell carcinoma: a simple immunostaining score.
Kovacs G; Billfeldt NK; Farkas N; Dergez T; Javorhazy A; Banyai D; Pusztai C; Szanto A
Histopathology; 2017 Jan; 70(2):273-280. PubMed ID: 27501523
[TBL] [Abstract][Full Text] [Related]
12. Axl Is a Potential Cancer Prognostic Marker for the Migration and Invasion of Nasopharyngeal Carcinoma.
Jiang C; Zhou L; Wang H; Zhang Q; Xu Y
Adv Clin Exp Med; 2016; 25(3):531-7. PubMed ID: 27629742
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets.
Caliò A; Brunelli M; Segala D; Pedron S; Remo A; Ammendola S; Munari E; Pierconti F; Mosca A; Bollito E; Sidoni A; Fisogni S; Sacco C; Canu L; Sentinelli S; Fraccon AP; Fiorentino M; Scott C; Milella M; Porta C; Argani P; Martignoni G
Pathology; 2020 Apr; 52(3):297-309. PubMed ID: 32107074
[TBL] [Abstract][Full Text] [Related]
14. Computational and Immunohistochemical Analyses Highlight AXL as a Potential Prognostic Marker for Ovarian Cancer Patients.
Lozneanu L; Pinciroli P; Ciobanu DA; Carcangiu ML; Canevari S; Tomassetti A; Căruntu ID
Anticancer Res; 2016 Aug; 36(8):4155-63. PubMed ID: 27466525
[TBL] [Abstract][Full Text] [Related]
15. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.
Rankin EB; Fuh KC; Castellini L; Viswanathan K; Finger EC; Diep AN; LaGory EL; Kariolis MS; Chan A; Lindgren D; Axelson H; Miao YR; Krieg AJ; Giaccia AJ
Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13373-8. PubMed ID: 25187556
[TBL] [Abstract][Full Text] [Related]
16. Expression of phosphorylated p21-activated kinase 4 is associated with aggressive histologic characteristics and poor prognosis in patients with surgically treated renal cell carcinoma.
Kang HW; Piao XM; Lee HY; Kim K; Seo SP; Ha YS; Kim YU; Kim WT; Kim YJ; Lee SC; Kim WJ; Shin EY; Kim EG; Yun SJ
Investig Clin Urol; 2021 Jul; 62(4):399-407. PubMed ID: 34085786
[TBL] [Abstract][Full Text] [Related]
17. Expression of RARRES1 and AGBL2 and progression of conventional renal cell carcinoma.
Peterfi L; Banyai D; Yusenko MV; Bjercke T; Kovacs G
Br J Cancer; 2020 Jun; 122(12):1818-1824. PubMed ID: 32307444
[TBL] [Abstract][Full Text] [Related]
18. M2 Macrophage Marker Chitinase 3-Like 2 (CHI3L2) Associates With Progression of Conventional Renal Cell Carcinoma.
Pusztai C; Yusenko MV; Banyai D; Szanto A; Kovacs G
Anticancer Res; 2019 Dec; 39(12):6939-6943. PubMed ID: 31810965
[TBL] [Abstract][Full Text] [Related]
19. Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.
Shi H; Sun Y; He M; Yang X; Hamada M; Fukunaga T; Zhang X; Chang C
Oncogene; 2020 Jan; 39(3):530-545. PubMed ID: 31501521
[TBL] [Abstract][Full Text] [Related]
20. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
